Cybin Inc. Common Stock

NASDAQ: HELP · Healthcare · Biotechnology

Canadian filerHQ Toronto, ONCIK 0001833141Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 52

v0.1 · 5/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ filing timeliness, listing tenure

Methodology →

Revenue TTM

$1.3M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$81.3M

Employees

Market cap

$312.2M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$81.3M-113.1M CAD2025

Total assets$179.9M258.6M CAD2025

Liabilities$6.3M7.9M CAD2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Cybin Inc. Common Stock earned -$81.3M in FY2025 net income.

Peers · Healthcare

Northwest Biotherapeutics, Inc.39D Verastem, Inc.48D Foghorn Therapeutics Inc.43D Cartesian Therapeutics, Inc.40D

Key facts

CEOMichael F. Cola

SectorHealthcare

IndustryBiotechnology

HeadquartersToronto, ON

ExchangeNASDAQ: HELP

Employees50

IPO date2019-09-13

Latest filings

40-F2026-06-29 6-K2026-06-29 6-K2026-06-25 6-K2026-06-25 6-K2026-06-11 6-K2026-06-01 6-K2026-05-04 6-K2026-04-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.